Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of CD5024 1% cream in papulopustular rosacea
2007-006673-91Phase 3Completed
- Sponsor
- Galderma
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivermectin in papulopustular rosacea, sponsored by Galderma. Primary endpoint: Primary safety assessment. Started May 2008; status: completed.
02
Drugs
ivermectin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on 2007-006673-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006673-91.